Table 1.

Predictors of receiving a resistance test

	No. participants	No. (%) with resistance test	Unadjusted OR	Adjusted OR* (95% CI)	p-value
	2155	1845 (85.6)
Age					0.36
18–29	523	439 (83.9)	0.72	0.81 (0.52, 1.25)
30–39	688	605 (87.9)	1.00	1.00
40–49	643	561 (87.2)	0.94	0.96 (0.63, 1.47)
≥50	301	240 (79.7)	0.54	0.67 (0.40, 1.11)
Gender					0.26
Male	1900	1673 (88.1)	1.00	1.00
Female	255	172 (67.5)	0.28	0.72 (0.41, 1.27)
Race					0.01
White	1579	1388 (87.9)	1.00	1.00
Black	340	259 (76.2)	0.44	0.57 (0.34, 0.97)
Hispanic	161	132 (82.0)	0.63	0.53 (0.26, 1.06)
Asian	36	27 (75.0)	0.41	0.26 (0.09, 0.73)
Other	39	39 (100.0)	∞	∞
HIV mode					0.005
MSM	1583	1412 (89.2)	1.00	1.00
Heterosexual	402	296 (73.6)	0.34	0.51 (0.30, 0.86)
IDU	60	44 (73.3)	0.33	0.26 (0.09, 0.74)
Other/unknown	110	93 (84.5)	0.66	1.10 (0.51, 2.35)
Year diagnosed					0.001
1982–2006	357	273 (76.5)	0.42	0.39 (0.24, 0.64)
2007–2008	341	293 (85.9)	0.78	0.75 (0.46, 1.24)
2009–2010	728	633 (87.0)	0.86	0.89 (0.59, 1.35)
2011–2013	729	646 (88.6)	1.00	1.00
CD4 count (cells/μL)					0.29
500–599	680	582 (85.6)	1.00	1.00
600–699	709	620 (87.4)	1.17	0.93 (0.62, 1.40)
≥700	766	643 (83.9)	0.88	0.74 (0.50, 1.10)
HIV RNA (copies/mL)					<0.001
0–399	104	56 (53.8)	0.15	0.13 (0.07, 0.24)
400–9,999	775	650 (83.9)	0.65	0.75 (0.52, 1.07)
10,000–99,999	1022	908 (88.8)	1.00	1.00
≥100,000	249	226 (90.8)	1.23	1.06 (0.60, 1.90)
Anti-HCV					0.47
No	1956	1683 (86.0)	1.00	1.00
Yes	129	103 (79.8)	0.64	1.32 (0.62, 2.78)
Region					0.97
Europe	1539	1335 (86.7)	1.00	1.00
United States	507	412 (81.3)	0.66	1.09 (0.46, 2.58)
Australia	109	98 (89.9)	1.36	0.93 (0.21, 4.23)

Analysis based on data from Europe, the United States and Australia.

^*Random effects logistic regression analysis (random effect for study site), adjusted for all other variables listed

MSM=men who have sex with men; IDU=injecting drug use; HCV=hepatitis C.